Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| No statute on record | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EIX, EMILY FAY | 1 | 52.2% | +64.7% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.4% |
| DAHLE, CHUN WU | 1 | 50.1% | +51.8% |
| JADHAO, SAMADHAN JAISING | 1 | 50.0% | +45.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | PUTTLITZ, KARL J | 85d overdue |
| 18012281 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | JADHAO, SAMADHAN JAISING | 49d overdue |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 16d |
| 18036813 | BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH) | EIX, EMILY FAY | 61d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1646 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036813 | BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH) | EIX, EMILY FAY | 1653 | DPOther | Non-Final OA | 61d | Pending | May 12, 2023 |
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | PUTTLITZ, KARL J | 1646 | Other | Non-Final OA | 85d overdue | Pending | May 09, 2023 |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 1641 | Other | Non-Final OA | 16d | Pending | Jan 16, 2023 |
| 18012281 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | JADHAO, SAMADHAN JAISING | 1672 | §112 | Non-Final OA | 49d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial